Natera (NASDAQ:NTRA) CEO Sells $1,476,113.45 in Stock

Key Points

• Natera CEO Steven Leonard Chapman sold 9,109 shares of the company's stock for approximately $1.48 million, reducing his ownership by 5.14% and leaving him with around 168,155 shares valued at roughly $27.25 million.
• The company's stock price increased by 0.4% to $161.61 on Wednesday, with a market cap of $22.18 billion and a PE ratio of -84.61.
• Natera's recent quarterly earnings report showed a revenue increase of 32.2% year-over-year, despite reporting a loss of ($0.74) earnings per share, missing analysts' expectations.

Natera, Inc. (NASDAQ:NTRA - Get Free Report) CEO Steven Leonard Chapman sold 9,109 shares of Natera stock in a transaction on Tuesday, September 30th. The stock was sold at an average price of $162.05, for a total value of $1,476,113.45. Following the sale, the chief executive officer owned 168,155 shares of the company's stock, valued at approximately $27,249,517.75. This trade represents a 5.14% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Steven Leonard Chapman also recently made the following trade(s):

• On Wednesday, October 1st, Steven Leonard Chapman sold 14,083 shares of Natera stock. The shares were sold at an average price of $160.00, for a total value of $2,253,280.00.
• On Tuesday, September 2nd, Steven Leonard Chapman sold 5,079 shares of Natera stock. The stock was sold at an average price of $166.53, for a total value of $845,805.87.
• On Friday, August 1st, Steven Leonard Chapman sold 5,807 shares of Natera stock. The shares were sold at an average price of $132.88, for a total value of $771,634.16.
• On Monday, July 28th, Steven Leonard Chapman sold 6,092 shares of Natera stock. The shares were sold at an average price of $139.81, for a total value of $851,722.52.
• On Monday, July 21st, Steven Leonard Chapman sold 1,622 shares of Natera stock. The shares were sold at an average price of $139.29, for a total value of $225,928.38.

Natera Stock Up 0.4%

Shares of NTRA traded up $0.64 during midday trading on Wednesday, reaching $161.61. The company had a trading volume of 1,583,819 shares, compared to its average volume of 1,079,070. Natera, Inc. has a 1-year low of $117.27 and a 1-year high of $183.00. The stock has a market cap of $22.18 billion, a PE ratio of -84.61 and a beta of 1.74. The firm has a 50 day simple moving average of $160.22 and a 200-day simple moving average of $156.35.

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The medical research company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.14). The business had revenue of $546.60 million for the quarter, compared to analyst estimates of $476.84 million. Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The firm's revenue for the quarter was up 32.2% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.30) earnings per share. Natera has set its FY 2025 guidance at EPS. As a group, sell-side analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Institutional Trading of Natera

Several institutional investors and hedge funds have recently made changes to their positions in NTRA. Roxbury Financial LLC boosted its stake in Natera by 12.5% in the 3rd quarter. Roxbury Financial LLC now owns 900 shares of the medical research company's stock worth $145,000 after purchasing an additional 100 shares during the period. Corient Private Wealth LLC increased its stake in Natera by 6.6% in the second quarter. Corient Private Wealth LLC now owns 5,796 shares of the medical research company's stock valued at $979,000 after acquiring an additional 360 shares during the last quarter. Osaic Holdings Inc. grew its stake in shares of Natera by 49.0% during the second quarter. Osaic Holdings Inc. now owns 9,319 shares of the medical research company's stock worth $1,562,000 after buying an additional 3,065 shares during the last quarter. American Trust acquired a new position in shares of Natera during the second quarter worth $226,000. Finally, China Universal Asset Management Co. Ltd. acquired a new position in Natera in the second quarter valued at $169,000. Institutional investors own 99.90% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the company. Stephens restated an "overweight" rating and issued a $183.00 price target on shares of Natera in a research note on Friday, August 15th. Evercore ISI raised Natera to a "strong-buy" rating and set a $170.00 target price for the company in a research report on Monday, July 28th. Barclays reaffirmed an "overweight" rating and set a $210.00 target price (up previously from $190.00) on shares of Natera in a report on Friday, August 8th. Morgan Stanley restated an "overweight" rating and issued a $195.00 target price on shares of Natera in a research report on Sunday, August 10th. Finally, Wells Fargo & Company started coverage on Natera in a research note on Monday, September 22nd. They set an "equal weight" rating and a $175.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, Natera currently has a consensus rating of "Buy" and an average price target of $192.88.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.